HC Wainwright Begins Coverage on Tvardi Therapeutics (NASDAQ:TVRD)

HC Wainwright started coverage on shares of Tvardi Therapeutics (NASDAQ:TVRD) in a research report issued to clients and investors on Monday, MarketBeat.com reports. The firm set a “buy” rating and a $9.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 211.42% from the stock’s previous close.

A number of other analysts have also commented on the company. BTIG Research reaffirmed a “buy” rating and issued a $15.00 target price on shares of Tvardi Therapeutics in a research report on Wednesday, April 1st. Wall Street Zen lowered Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, April 10th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Tvardi Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $46.17.

Tvardi Therapeutics Stock Performance

Shares of TVRD opened at $2.89 on Monday. The company has a market capitalization of $27.11 million, a PE ratio of -0.93 and a beta of 0.33. Tvardi Therapeutics has a 12 month low of $2.75 and a 12 month high of $43.65. The stock’s 50-day moving average price is $3.36 and its two-hundred day moving average price is $3.79.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08). Equities research analysts predict that Tvardi Therapeutics will post -2.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Tvardi Therapeutics

Several institutional investors have recently bought and sold shares of the company. Arax Advisory Partners lifted its position in shares of Tvardi Therapeutics by 277.2% during the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after acquiring an additional 6,173 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Tvardi Therapeutics during the second quarter worth $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Tvardi Therapeutics during the second quarter worth $43,000. HRT Financial LP purchased a new stake in shares of Tvardi Therapeutics during the fourth quarter worth $47,000. Finally, XTX Topco Ltd purchased a new stake in shares of Tvardi Therapeutics during the fourth quarter worth $55,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.